Insta
Institute Of Life Sciences Successfully Develops Antibodies Against Chikungunya; Next Step Developing Antivirals
The ILS has also entered into a non-exclusive license for product commercialisation. (image via ISC website)
The Institute of Life Sciences (ILS) functioning under the Department of Biotechnology has successfully developed antibodies against the Chikungunya viral infection (CHIKV). The ILS has also entered into a non-exclusive license for product commercialisation, The Hindu reports.
Dr Soma Chattopadhayay a senior molecular virologist at the ILS laboratory headed the decade-long research following which the antibodies were developed. The ILS is looking to partner with a biotechnology-based company for product commercialisation and marketing of the antibodies in a 60:40 profits sharing basis.
"Generation of antibodies has had a significant impact on the progress of CHIKV-based research. It will help researchers unravel myriad aspects of virus pathogenesis," Dr Chattopadhyay said.
She adds that the research communities are a step closer to developing efficacious antivirals and control strategies against Chikungunya virus, as the research sheds light upon the CHIKV infection biology antibodies.
Sources in the ILS said the antibodies against CHIKV has received a tremendous response, and research laboratories across the world are purchasing them.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.
Latest
